Eugene Washington - Johnson Johnson Independent Director
JNJ Stock | EUR 146.60 1.20 0.83% |
Director
Dr. A. Eugene Washington, M.D., M.Sc. is an Independent Director of the Company. He is currently Duke Universitys Chancellor for Health Affairs and the President and Chief Executive Officer of the Duke University Health System. Previously he was Vice Chancellor of Health Sciences, Dean of the David Geffen School of Medicine at UCLA Chief Executive Officer of the UCLA Health System and Distinguished Professor of Gynecology and Health Policy at UCLA. Prior to UCLA, he served as Executive Vice Chancellor and Provost at the University of California, San Francisco from 2004 to 2010. Dr. Washington cofounded UCSFs Medical Effectiveness Research Center for Diverse Populations in 1993 and served as Director until 2005. He was Chair of the Department of Obstetrics, Gynecology, and Reproductive Sciences at UCSF from 1996 to 2004. Dr. Washington also cofounded the UCSFStanford Evidencebased Practice Center and served as its first Director from 1997 to 2002. Prior to UCSF, Dr. Washington worked at the Centers for Disease Control and Prevention. Dr. Washington was elected to the National Academy of Sciences Institute of Medicine in 1997, where he served on its governing Council. He was founding Chair of the Board of Governors of the PatientCentered Outcomes Research Institute, served as a member of the Scientific Management Review Board for the NIH, and also served as Chair of the Board of Directors of both the California HealthCare Foundation and The California Wellness Foundation. Dr. Washington currently serves on the Boards of Directors of the Kaiser Foundation Hospitals and Kaiser Foundation Health Plan, Inc. since 2012.
Age | 67 |
Tenure | 12 years |
Phone | 732 524 0400 |
Web | https://www.jnj.com |
Johnson Johnson Management Efficiency
The company has return on total asset (ROA) of 0.0871 % which means that it generated a profit of $0.0871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2379 %, meaning that it generated $0.2379 on every $100 dollars invested by stockholders. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Craig Jacobson | NorAm Drilling AS | 65 | |
Randall Findlay | Superior Plus Corp | 67 | |
Peter Murphy | NorAm Drilling AS | 55 | |
Michael Kreger | NorAm Drilling AS | 33 | |
Peter Kern | NorAm Drilling AS | 50 | |
David Smith | Superior Plus Corp | 59 | |
Robert Engbloom | Superior Plus Corp | 64 | |
Catherine Best | Superior Plus Corp | 64 | |
Ross Levinsohn | NorAm Drilling AS | 54 | |
Laura Walker | NorAm Drilling AS | 60 | |
Eugene Bissell | Superior Plus Corp | 64 | |
Patrick Gottschalk | Superior Plus Corp | 54 | |
Walentin Mirosh | Superior Plus Corp | 71 | |
Richard Bradeen | Superior Plus Corp | 61 | |
James Arestia | NorAm Drilling AS | N/A | |
Mary Jordan | Superior Plus Corp | 58 | |
Douglas Harrison | Superior Plus Corp | 58 |
Management Performance
Return On Equity | 0.24 | |||
Return On Asset | 0.0871 |
Johnson Johnson Leadership Team
Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dirk Brinckman, Chief Officer | ||
Jennifer Doudna, Independent Director | ||
Alex Gorsky, Chairman of the Board, CEO | ||
William Perez, Independent Director | ||
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer | ||
Marillyn Hewson, Independent Director | ||
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer | ||
Mary Coleman, Independent Director | ||
Michael Ullmann, Vice President General Counsel | ||
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals | ||
Joseph CPA, Ex CFO | ||
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals | ||
Mary Beckerle, Director | ||
Sandra Peterson, Group Worldwide Chairman | ||
Scott Davis, Director | ||
Louise Mehrotra, Vice President Investor Relations | ||
Robert Decker, Controller Officer | ||
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices | ||
Ronald Williams, Independent Director | ||
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
James Swanson, Ex Officer | ||
Anne Mulcahy, Lead Independent Director | ||
Joseph Wolk, Vice President - Investor Relations | ||
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer | ||
Jessica Moore, VP Relations | ||
Ian Davis, Independent Director | ||
Paulus Stoffels, Chief Scientific Officer, Worldwide Chairman - Pharmaceuticals Group | ||
Mark McClellan, Independent Director | ||
Charles Prince, Independent Director | ||
Eugene Washington, Independent Director | ||
Elizabeth Forminard, Exec Counsel | ||
Dominic Caruso, CFO, Vice President - Finance | ||
Peter Fasolo, Vice President - Global Human Resources | ||
Susan Lindquist, Independent Director |
Johnson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.24 | |||
Return On Asset | 0.0871 | |||
Profit Margin | 0.19 % | |||
Operating Margin | 0.27 % | |||
Current Valuation | 443.95 B | |||
Shares Outstanding | 2.6 B | |||
Shares Owned By Insiders | 0.09 % | |||
Shares Owned By Institutions | 71.60 % | |||
Price To Earning | 29.33 X | |||
Price To Book | 6.28 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Johnson Stock please use our How to Invest in Johnson Johnson guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Johnson Stock analysis
When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |